Full-Time
Account Executive
Laboratorio Diagnóstico de Análisis Clínicos
Siemens Healthineers
10,001+ employees
Healthcare technology and services provider
No salary listed
Lugo, Spain + 2 more
More locations: Santiago de Compostela, Municipality of Santiago de Compostela, A Coruña, Spain | A Coruña, Spain
In Person
Travel throughout the assigned northern Spain territory is required.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to Siemens Healthineers
See people who can refer or advise you
- A Licenciatura or Ingeniería in the health field is required.
- At least four years of experience in the in vitro diagnostics field is required.
- A minimum English level of B2 under the Common European Framework of Reference is required.
- Availability to travel throughout the assigned territory is required.
- A valid driver's license is required.
- Grow the market share in the Galicia area of influence.
- Manage the sales process for the clinical analysis portfolio, including market prospecting, product promotion, order management and execution, customer follow-up, and customer retention.
- Maintain relationships across hospital structures, including laboratories, management, finance departments, purchasing centers, and infrastructure teams.
- A specialization in clinical analysis is desirable.
- Experience designing global solutions for clinical laboratories across pre-analytical, analytical, and post-analytical phases is desirable.
Siemens Healthineers provides medical technologies and services that help hospitals diagnose and treat patients. It offers imaging systems (MRI, CT, and ultrasound), laboratory diagnostics, and digital health software that uses data to support clinical decisions. The company differentiates itself with a broad portfolio, a global service network, and a long history of engineering and medical innovation. Its goal is to improve patient care and streamline clinical workflows worldwide through reliable technology and integrated solutions.
Company Size
10,001+
Company Stage
IPO
Headquarters
Forchheim, Germany
Founded
1847
Get referred to Siemens Healthineers
See people who can refer or advise you
Simplify's Take
What believers are saying
- Imaging grew 6.1% in Q2 2026, with 22.4% adjusted EBIT margin.
- Atellica capillary testing and brain biomarker launches expand consumables and research workflows.
- ARPA-H funding and Stryker partnership position Siemens for autonomous stroke robotics by 2031.
What critics are saying
- Reuters on July 31, 2026 cut guidance to 3.5%-4% as China diagnostics weakened.
- Diagnostics China pricing, VBP, and platform migration are destroying revenue through 2027.
- A failed Siemens AG spin-off or diagnostics carve-out would delay management focus and capital returns.
What makes Siemens Healthineers unique
- Siemens Healthineers pairs imaging, diagnostics, and therapy across hospitals, unlike point-solution rivals.
- Varian extends the platform from cancer into osteoarthritis and essential-tremor procedures.
- The August 20, 2026 ARPA-H award validates Siemens' robotics and MRI integration stack.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Holidays
Parental Leave
Childcare Support
401(k) Retirement Plan
Training Programs
Growth & Insights and Company News
6 month growth
↑ 6%1 year growth
↑ 6%2 year growth
↑ 6%The Advanced Research Projects Agency for Health has awarded Siemens Healthineers up to $31.1 million over five years to develop autonomous remote endovascular robotics for acute stroke treatment. Siemens will contribute an additional $5.4 million, bringing total investment to $36.5 million. The technology aims to enable robots to perform mechanical thrombectomy — a procedure that removes blood clots from brain blood vessels — without direct human input. Currently, only an estimated 12% of 335,000 eligible US stroke patients receive this treatment annually, as more than half the population lives over an hour from a thrombectomy-capable clinic. The funding is part of ARPA-H's Autonomous Interventions and Robotics programme. Stryker is participating as a sub-awardee, building on a 2025 partnership with Siemens.
Siemens Healthineers has launched capillary blood testing on its Atellica CH, IM, and CI Analysers after receiving CE-mark approval for 24 assays. The capability enables clinical laboratories to perform common tests including metabolic panels, lipid panels, thyroid, Vitamin D, and HbA1c using finger prick or heel stick samples rather than standard blood draws. Capillary testing offers a patient-friendly alternative for individuals with difficult veins, low blood volume, needle phobia, or disabilities. The validated claims provide laboratories with confidence in test results whilst expanding testing capabilities using existing infrastructure. In the United States, Siemens Healthineers currently offers four assays with capillary claims and is pursuing additional approvals with the FDA. The company aims to make testing more accessible and efficient across core laboratory settings.
AiM Medical Robotics has signed an agreement with Siemens Healthineers to develop a software interface connecting AiM's MRI-compatible robotic neurosurgery platform with Siemens' MAGNETOM MRI scanners. The integration will apply to Siemens' 1.5T, 3T and 0.55T MRI systems. The interface is designed to enable real-time, in-bore neurosurgical procedures, supporting image-guided therapies for neurostimulator lead placement, tumour and epilepsy ablation, biopsies and therapeutic delivery. AiM founder and CEO Gregory Fischer said the collaboration validates the company's technology and expands the ecosystem for precision robotics in image-guided operating suites. AiM specialises in MRI-compatible robotic platforms for neurosurgery. In May 2024, the company partnered with Brigham and Women's Hospital to validate its robot for deep-brain stimulation in Parkinson's disease patients.
Siemens Healthineers reported strong performance in its Imaging and Precision Therapy segments during Q2 2026, with Imaging growing 6.1% and achieving a 22.4% adjusted EBIT margin. Precision Therapy grew 4.7%, with margin expansion of around 150 basis points year-over-year. However, the Diagnostics segment declined 6% due to structural market rebasing in China. The company updated its fiscal 2026 revenue growth outlook to 4.5% to 5%, down from previous expectations, whilst maintaining adjusted EPS guidance between €2.20 and €2.30 despite supply chain inflation pressures. Siemens Healthineers reported 16% year-over-year adjusted EPS growth and strong free cash flow with a 0.81 conversion rate. The company is preparing for a strategic carve-out of its Diagnostics business and its upcoming spin-off from Siemens.
Siemens Healthineers has cut its revenue growth outlook for the 2026 financial year to 4.5–5.0%, down from 5–6%, as its diagnostics division struggles in China. The company also reduced its expected earnings per share range to €2.20–2.30 from €2.20–2.40. China, which accounts for 10% of revenue and is the company's second-largest market, saw diagnostics revenue decline 6.5% to €985 million year-on-year due to lower reimbursement rates and volume-based procurement. CEO Bernd Montag called it a "perfect storm" and said the company is considering spinning off the diagnostics division. Second-quarter adjusted earnings before interest and taxes fell 3.8% to €5.681 billion, missing analyst expectations. The company anticipates additional supply chain costs and more pronounced inflation ahead. Shares fell 3.3% following the announcement.